PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
Alessandro Di Federico, Andrea De Giglio, Claudia Parisi, Francesco Gelsomino, Andrea Ardizzoni
Topics & Concepts
ImmunotherapyMedicineChemotherapyOncologyInternal medicineOverall survivalCancerCancer Immunotherapy and BiomarkersLymphoma Diagnosis and TreatmentLung Cancer Treatments and Mutations